Popis: |
T-cell acute lymphoblastic leukemia (T-ALL) represents a particularly aggressive subtype of leukemia with no targeted therapies or immune interventions. Currently, in response to intensive chemotherapy, ~25% of pediatric and 50% of adult patients undergo relapse and succumb to this therapy-resistant disease. Patients that relapse have poor outcomes, with Citation Format: Mark Gower, Minerva Fernandez, Andrea Aruda, Mark Minden, Johann Hitzler, Anastasia Tikhonova. Dissecting immune microenvironment of T-cell acute lymphoblastic leukemia. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr NG14. |